Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
CodeBreaK100: Sotorasib in pretreated KRAS p.G12C mNSCLC
Dr Ferdinandos Skoulidis - MD Anderson Cancer Center, Houston, USA
CodeBreaK100: Sotorasib in pretreated KRAS p.G12C mNSCLC ( Dr Ferdinandos Skoulidis - MD Anderson Cancer Center, Houston, USA )
9 Jun 2021
LEAP-004: Lenvatinib + pembrolizumab for patients with advanced melanoma and con...
Dr Ana Arance - Hospital Clínic de Barcelona, Barcelona, Spain
LEAP-004: Lenvatinib + pembrolizumab for patients with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor ( Dr Ana Arance - Hospital Clínic de Barcelona, Barcelona, Spain )
8 Jun 2021
OncoAlert and ecancer ASCO roundup - Day 3
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer ASCO roundup - Day 3 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
8 Jun 2021
OncoAlert and ecancer ASCO roundup - Day 2
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer ASCO roundup - Day 2 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
8 Jun 2021
OncoAlert and ecancer ASCO roundup - Day 1
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer ASCO roundup - Day 1 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
8 Jun 2021
Clinical trials participation is directly influenced by the information received...
Dr Daniel Vorobiof - Belong.Life, New York, USA
Clinical trials participation is directly influenced by the information received by cancer patients and caregivers ( Dr Daniel Vorobiof - Belong.Life, New York, USA )
4 Jun 2021
Long term outcome of enfortumab vedotin + pembrolizumab in first line locally ad...
Dr Terence Friedlander - UCSF, San Francisco, USA
Long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma ( Dr Terence Friedlander - UCSF, San Francisco, USA )
4 Jun 2021
OncoAlert and ecancer weekly roundup for April 19 - 25, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer weekly roundup for April 19 - 25, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
26 Apr 2021
SMMART Program: A multi-omics tumour board with a focus on breast cancer
Dr Ben Kong - Oregon Health & Science University, Portland, USA
SMMART Program: A multi-omics tumour board with a focus on breast cancer ( Dr Ben Kong - Oregon Health & Science University, Portland, USA )
13 Apr 2021
PC14586: The first orally bioavailable small molecule reactivator of Y220C mutan...
Dr Melissa Dumble - PMV Pharmaceuticals, Cranbury, USA
PC14586: The first orally bioavailable small molecule reactivator of Y220C mutant p53 in clinical development ( Dr Melissa Dumble - PMV Pharmaceuticals, Cranbury, USA )
13 Apr 2021
Adjuvant therapy with nivolumab combined with ipilimumab vs nivolumab alone in p...
Prof Georgina Long - University of Sydney, Sydney, Australia
Adjuvant therapy with nivolumab combined with ipilimumab vs nivolumab alone in patients with resected stage IIIB-D/IV melanoma ( Prof Georgina Long - University of Sydney, Sydney, Australia )
13 Apr 2021
Highlights from AORTIC Cancer Genomics Conference 2021
Dr Hannah Ayettey - National Radiotherapy Oncology and Nuclear Medicine Center, ...
Highlights from AORTIC Cancer Genomics Conference 2021 ( Dr Hannah Ayettey - National Radiotherapy Oncology and Nuclear Medicine Center, Accra, Ghana )
30 Mar 2021